FDA Grants IDE Approval for Solenic Medical's SOLA-2 Pivotal Trial in Periprosthetic Joint Infections
核心洞察
Solenic Medical (搜索) received FDA Investigational Device Exemption approval to launch a pivotal clinical trial of its SOLA-2 Alternating Magnetic Field System (搜索) for periprosthetic joint infections (搜索).
The SOLA-2 system is a first-in-class non-invasive technology designed to disrupt bacterial biofilms on infected orthopedic implants by precisely heating metallic implant surfaces.
Periprosthetic joint infections (搜索) carry an estimated global healthcare cost burden exceeding $6 billion annually, projected to surpass $15 billion per year by 2035.
Solenic Medical (搜索) announced today that the U.S. Food and Drug Administration has approved its Investigational Device Exemption (IDE) application, authorizing the launch of a pivotal clinical trial for the SOLA-2 Alternating Magnetic Field (AMF) System in patients with periprosthetic joint infections (搜索) (PJI). The regulatory milestone clears the way for what could become the first non-invasive treatment designed to eradicate biofilm on infected orthopedic implants, with patient enrollment expected to commence in the second half of 2026.
"FDA IDE approval marks a pivotal milestone for Solenic Medical (搜索) and validates years of scientific and clinical development," said Bart Bandy, Chief Executive Officer of Solenic Medical. "We believe SOLA-2 has the potential to fundamentally transform how periprosthetic joint infections (搜索) are treated and generate the positive clinical evidence needed to bring a potentially paradigm-shifting technology to patients, physicians, and healthcare systems worldwide."
The Clinical and Economic Burden of PJI
Periprosthetic joint infections (搜索) represent one of the most serious and costly complications in orthopedic surgery. These infections occur when bacteria colonize the area around an artificial joint implant, forming biofilm on implant surfaces that renders them more resistant to antibiotics and the host immune response. Hip, knee, and shoulder PJI impose an estimated global healthcare cost burden of over $6 billion annually, with projections exceeding $15 billion per year by 2035.
Current treatment options often involve prolonged antibiotic therapy, surgical debridement, implant retention in selected patients, or staged revision surgery requiring implant removal and replacement. Despite this significant clinical and economic burden, treatment approaches have remained relatively unchanged for decades and carry meaningful failure rates.
How SOLA-2 Works
The SOLA-2 system leverages Solenic's proprietary Alternating Magnetic Field technology to precisely heat the outer surface of metallic implants, thereby disrupting bacterial biofilms—the underlying driver of implant infections—without requiring implant removal. This non-invasive approach targets the entire implant surface, potentially reducing the need for more invasive surgical interventions.
"Periprosthetic joint infection remains one of the most challenging problems in arthroplasty care," said Antonia Chen, M.D./M.B.A., Chair and Professor of Orthopedic Surgery and President of the American Association of Hip and Knee Surgeons, who serves on Solenic's Medical Advisory Board. "A non-invasive technology designed to safely target biofilm on the entire implant surface would represent an important advancement in infection therapy for patients and surgeons, particularly if it reduces the need for more invasive procedures."
Pivotal Trial Design and Prior Evidence
The FDA-authorized pivotal study will evaluate the safety and effectiveness of SOLA-2 in patients with infected knee replacements through enrollment at leading national orthopedic and academic centers. The trial is intended to serve as the foundation for future regulatory submissions supporting FDA marketing authorization.
Solenic previously evaluated the SOLA-2 AMF System in an early feasibility study involving adult patients diagnosed with knee implant infection undergoing debridement, antibiotics, and implant retention (DAIR). The study demonstrated that SOLA-2 performed as intended with no device-related adverse events and helped inform the design of the now-authorized pivotal trial.
Clinical site activation across leading centers in the United States is underway, with patient enrollment expected to commence in the second half of 2026. SOLA-2 remains an investigational device and has not been approved or cleared by the FDA for commercial use.